Petros pharmaceuticals, inc. through exclusive marketing agreement with hims & hers health, inc. generates 476% year-over-year growth of stendra tablet sales

New york, nov. 3, 2021 /prnewswire/ -- petros pharmaceuticals, inc. (petros, nasdaq: ptpi), a leading provider of therapeutics for men's health, today announces a 476% growth year-over-year of stendra tablet sales as part of an exclusive digital health marketing agreement with hims & hers health, inc. ("hims & hers" or "hims"), the multi-specialty telehealth platform focused on providing modern personalized health and wellness experiences to consumers. the companies also announce the availability of additional dosages of stendra through the hims & hers platform, further expanding the partnership.
PTPI Ratings Summary
PTPI Quant Ranking